References
- Culyer AJ. Cost Containment in Europe. Health Care Financ. Rev (Annual Suppl.), 21-32(1989).
- Belien P. Healthcare Reform in Europe. Phalmacoeconomics 10\(Suppl. 2), 94–99 (1996).
- Hall J. Incremental change in the Australian health care system. Health Affairs 18(3), 95–110 (1999).
- Vandergrift M, Kanvos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 41(3), 241–260 (1997).
- Paul JE, Trueman P. 'Fourth hurdle reviews', NICE, and database applications. Phalmacoepidemiol Drug Sal 10, 429–438 (2001).
- ••Nice overview of the fourth hurdle and theimpact of NICE.
- Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry. Brit Merl 313(7048), 33–35 (1996).
- Freemantle N. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals? Health Policy 46(3), 225–265 (1999).
- Keech M. Using health outcomes data to inform decision-making. A pharmaceutical industry perspective. Phatmacoeconornics 19\(Suppl. 2), 27–31 (2001).
- Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health 4 (3), 225–250 (2001).
- Gold MR, Siegel JE, Russell LB, et al. Cost- Effectiveness in health and medicine. Oxford University Press. New York, NY, USA (1996).
- ••Absolute 'must-read' for anyone interestedin the methodological issues of assessing the economic value of pharmaceuticals.
- BIWA: Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA (1995).
- Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am. Psych. 156(1), 5–10 (1999).
- DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. PhatmacoEconomics 19(7), 753–766 (2001).
- Duley L, Villar J. Clinical Bids. BMJ Books, London, UK, 42–43 ( 2002).
- Mullins CD, Lyons BM, Ahn J. Pharmaceutical market impact of the early 1990's health care debate. j Res. Pharm. Econom. 111(2), 1–22 (2001).
- •Describes the impact of the Clinton healthcare reform debate on the value of US-based drug companies in terms of the market value of pharmaceutical firms.
- Nicholson W Strategy and Game Theory. In: Mcroeconomic Themy Basic Principles and Extensions 4th Edition. The Dryden Press, New York, NY, USA, 598–601 (1989).
Websites
- Kanavos P, Trueman P, Bosileva A. Can Economic Evaluation Guidelines Improve Efficiency in Resource Allocation? The Cases of Portugal, the Netherlands, Finland and the UK. London School of Economics & Political Science, UK. Available from: www.lse.ac.uk/Depts/isehsc/papers/ Discussion_Papers/dp15.final.pdf Accessed January 2003.
- Wait S. Caveats of Randomized Clinical Trials for Economic Analysis 14 Dec 2001 Available from: http://web.mit.edu/popi/wait.slides.pdf Presented at the POPI (Program on Pharmaceutical Industry) Symposium at the MIT Sloan School of Management titled 2001 The Future of the Pharmaceutical Industry. Accessed 20th August 2002.
- Background of NICE. Available from: http://www.nice.org.ukkat.asp?c=137 Accessed February 13, 2003.
- AMCP Formulary Submission guidelines. Available from: www.amcp.org/ publications/format.pdf Accessed February 13, 2003.
- •• Describes the current requirements for pharmaceutical companies who wish to provide dossiers to managed care decision-makers in the USA.
- The cost of pharmacoeconomics (Published August 2001 Source CMR International). Synopsis of a health economics industry discussion meeting in May 2001 organized by CMR International and the Office of Health Economics Available from: www.inpharm.com/intelligence/ cmr050801.html Accessed February 13, 2003.
- Cost Effective Healthcare Solutions: The Strategic Impact of Pharmacoeconomics in Key Markets (Published March 2000 Source Reuters Business Insights) Available from: www.inpharm.com/intelligence/ rbi040300.html Accessed February 13, 2003.
- Ogg MS, van den Haak MA, Halliday RG. Activities of the International Pharmaceutical Industry in 2000, Pharmaceutical Investment and Output. Available from: www.cmr.org/pdfs/pio.pdf Accessed February 13, 2003.
- R & D Briefing No 33. Market access for new medicines: Are companies changing their strategies? Available from: www.cmr.org/pdfs/R&D33.pdfn Accessed February 13, 2003.
- Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the PBAC: Part III - Preparing the main body of a major submission. Available from: www.health.gov.au/pbs/pubs/pharmpac/ section3.htm Accessed February 13, 2003.
- Hill J, Kirchner A, Holmes A. Pharmaceuticals Industry Action Agenda September 2001. Available from: www.isr.gov.au/library/content_library/ PharmPapersepOl.pdf Accessed February 13, 2003.
- Inquiry into the National Institute for Clinical Excellence. Submission from the Association of the British Pharmaceutical Industry. 10 January, 2002. Available from: www.abpi.org.uldinformation Accessed February 13, 2003.
- van den Haak M. "Fewer New Launches in 2000", CMR International news ISSN 1368 5368;19 (1) 2001: 10–14. Available from: www.cmr.org/pdfs/apri12001.pdf Accesssed February 13, 2003.